Study Stopped
Lack of efficacy
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
VISTA-16
1 other identifier
interventional
5,189
17 countries
362
Brief Summary
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started May 2010
362 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 19, 2010
CompletedStudy Start
First participant enrolled
May 1, 2010
CompletedFirst Posted
Study publicly available on registry
May 25, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedOctober 31, 2012
October 1, 2012
1.8 years
April 19, 2010
October 30, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
Primary Objective of the Study
To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization.
16 weeks
Secondary Outcomes (1)
Secondary Objective of the Study
2, 4, 8, 16 weeks and 6 months
Study Arms (2)
A-002 500 mg
EXPERIMENTALOnce daily oral administration
Matched Placebo
PLACEBO COMPARATOROnce daily oral administration
Interventions
A-002 administered once daily in addition to atorvastatin and standard of care
Placebo administered once daily in addition to atorvastatin and standard of care
Eligibility Criteria
You may qualify if:
- Men and women ≥40 years of age
- Written informed consent from the subject
- A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI)
- Unstable angina is defined as:
- Chest pain symptomatic of ischemia or angina occurring at rest or on minimal exertion with a pattern of increasing frequency or severity, lasting \>10 minutes and consistent with myocardial ischemia within 24 hours prior to hospitalization and
- New or dynamic ST-segment depression or prominent T-wave inversion changes in at least 2 contiguous leads and
- In addition subjects meeting the above criteria for unstable angina must also have either troponin I, troponin T or CKMB above the LLD but below the 99th percentile of the upper reference limit (URL) and not due to cardioversion or underlying cardiovascular (CHF, cardiomyopathy) or renal disease
- NSTEMI is defined as:
- Chest pain symptomatic of ischemia
- No electrocardiogram (ECG) changes, or ST-depression, or T wave changes(i.e., no new Q waves on serial ECGs)and
- Increase in cardiac troponin \> local limit for the definition of myocardial infarction or increase in CK-MB isoenzyme \> URL
- STEMI is defined as:
- Chest pain symptomatic of ischemia
- ST segment elevation and associated T wave changes or ST-segment elevation of at least 2 mm in 2 contiguous leads, either of which persisting for longer than 15 minutes and
- Increase in cardiac troponin \> local limit for the definition of myocardial infarction or increase in CK-MB \>URL
- +15 more criteria
You may not qualify if:
- Subjects enrolled in another experimental (interventional)protocol within the past 30 days prior to Screening.
- Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision or radiation therapy (e.g. chemotherapy)
- The presence of any severe liver disease with cirrhosis, active hepatitis, active chronic hepatitis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 x ULN, biliary obstruction with hyperbilirubinemia (total bilirubin \>2 x ULN)
- Active cholecystitis, gall bladder symptoms, or any hepatobiliary abnormalities
- The presence of severe renal impairment (creatinine clearance \[CrCl\] \<30 mL/min or creatinine \>3 x ULN),nephrotic syndrome, or subjects undergoing dialysis
- Uncontrolled diabetes mellitus (known hemoglobin A1c \[HbA1c\] \>11% within the last 1 month prior to Screening)
- Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or females of childbearing potential who have a positive pregnancy test during screening evaluation. Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double barrier method (diaphragm with spermicidal foam or jelly, or a condom).
- Subjects who have a history of alcohol or drug abuse within 1 year of study entry
- Subjects living too far from participating center or unable to return for follow-up visits
- Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
- Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection
- Acute bacterial, fungal or viral infection
- Subjects currently taking drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
- Subjects with New York Heart Association (NYHA) Class III or IV heart failure, or if known, left ventricular ejection fraction (LVEF) \<30
- Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (362)
Investigator Site 1064
Birmingham, Alabama, 35205, United States
Investigator Site 1063
Birmingham, Alabama, 35235, United States
Investigator Site 1065
Birmingham, Alabama, 35243, United States
Investigator Site 1020
Huntsville, Alabama, 35801, United States
Investigator Site 1133
Mobile, Alabama, 36608, United States
Investigator Site 1019
Tucson, Arizona, 85724, United States
Investigator Site 1132
Escondido, California, 92025, United States
Investigator Site 1087
Mission Viejo, California, 92691, United States
Investigator Site 1005
Torrance, California, 90502, United States
Investigator Site 1079
Aurora, Colorado, 80012, United States
Investigator Site 1006
Colorado Springs, Colorado, 80909, United States
Investigator Site 1050
Denver, Colorado, 80218, United States
Investigator Site 1045
Denver, Colorado, 80220, United States
Investigator Site 1061
Fort Collins, Colorado, 80528, United States
Investigator Site 1054
Littleton, Colorado, 80120, United States
Investigator Site 1140
Wheat Ridge, Colorado, 80033, United States
Investigator Site 1111
Hartford, Connecticut, 06102, United States
Investigator Site 1028
Newark, Delaware, 19718, United States
Inevestigator Site 1074
Washington D.C., District of Columbia, 20010, United States
Investigator Site 1030
Washington D.C., District of Columbia, 20037, United States
Investigator Site 1117
Washington D.C., District of Columbia, 20422, United States
Investigator Site 1022
Clearwater, Florida, 33756, United States
Investigator Site 1051
Clearwater, Florida, 33756, United States
Investigator Site 1112
Fort Lauderdale, Florida, 33316, United States
Investigator Site 1049
Lakeland, Florida, 33805, United States
Investigator Site 1124
Miami Beach, Florida, 33140, United States
Investigator Site 1095
Tallahassee, Florida, 32308, United States
Investigator Site 1058
Tampa, Florida, 33613, United States
Investigator Site1110
Atlanta, Georgia, 30342, United States
Investigator Site 1011
Augusta, Georgia, 30901, United States
Investigator Site 1114
Macon, Georgia, 31201, United States
Investigator Site 1086
Naperville, Illinois, 60540, United States
Investigator Site 1125
Oak Lawn, Illinois, 60453, United States
Investigator Site 1044
Covington, Louisiana, 70433, United States
Investigator Site 1069
New Orleans, Louisiana, 70112, United States
Investigator Site 1066
New Orleans, Louisiana, 70115, United States
Investigator Site 1144
Shreveport, Louisiana, 71101, United States
Investigator Site 1060
Flint, Michigan, 48532, United States
Investigator Site 1136
Novi, Michigan, 48374, United States
Investigator Site 1137
Petoskey, Michigan, 49770, United States
Investigator Site 1048
Traverse City, Michigan, 49684, United States
Investigator Site 1034
Duluth, Minnesota, 55807, United States
Investigator Site 1046
Minneapolis, Minnesota, 55407, United States
Investigator Site 1033
Minneapolis, Minnesota, 55417, United States
Investigator Site 1016
Tupelo, Mississippi, 38801, United States
Investigator Site 1027
Kalispell, Montana, 59901, United States
Investigator Site 1092
Missoula, Montana, 59802, United States
Investigator Site 1032
Omaha, Nebraska, 68131, United States
Investigator Site 1031
Ridgewood, New Jersey, 07450, United States
Investigator Site 1057
Johnson City, New York, 13790, United States
Investigator Site 1101
Charlotte, North Carolina, 28204, United States
Investigator Site 1100
Gastonia, North Carolina, 28054, United States
Investigator Site 1121
Raleigh, North Carolina, 27609, United States
Investigator Site 1088
Raleigh, North Carolina, 27610, United States
Investigator Site 1123
Wilmington, North Carolina, 28401, United States
Investigator Site 1075
Winston-Salem, North Carolina, 27103, United States
Investigator Site 1108
Fargo, North Dakota, 58122, United States
Investigator Site 1024
Canton, Ohio, 44710, United States
Investigator Site 1143
Cleveland, Ohio, 44106, United States
Investigator 1141
Cleveland, Ohio, 44109, United States
Investigator Site 1131
Mansfield, Ohio, 44901, United States
Investigator Site 1004
Oklahoma City, Oklahoma, 73104, United States
Investigator Site 1026
Oklahoma City, Oklahoma, 73112, United States
Investigator Site 1122
Portland, Oregon, 97239, United States
Investigator Site 1107
Danville, Pennsylvania, 17822, United States
Investigator Site 1029
Doylestown, Pennsylvania, 18901, United States
Investigator Site 1134
Lancaster, Pennsylvania, 17602, United States
Investigator Site 1018
York, Pennsylvania, 17405, United States
Investigator Site 1072
Providence, Rhode Island, 02906, United States
Investigator Site 1038
Rapid City, South Dakota, 55701, United States
Investigator Site 1138
Sioux Falls, South Dakota, 57104, United States
Investigator Site 1014
Jackson, Tennessee, 38305, United States
Investigator Site 1047
Knoxville, Tennessee, 37917, United States
Investigator Site 1115
Dallas, Texas, 75216, United States
Investigator Site 1040
Dallas, Texas, 75226, United States
Investigator Site 1037
Houston, Texas, 77030, United States
Investigator Site 1130
Houston, Texas, 77030, United States
Investigator Site 1025
Tyler, Texas, 75501, United States
Investigator Site 1139
Layton, Utah, 84041, United States
Investigator Site 1056
Harrisonburg, Virginia, 22801, United States
Investigator Site 1083
Norfolk, Virginia, 23507, United States
Investigator Site 1043
Richmond, Virginia, 23249, United States
Investigator Site 1042
Marshfield, Wisconsin, 54449, United States
Investigator Site 6106
Canberra, Australian Capital Territory, Australia
Investigator Site 6114
Gosford, New South Wales, 2250, Australia
Investigator Site 6120
Kingswood, New South Wales, 2747, Australia
Investigator Site 6113
Cairns, Queensland, 4870, Australia
Investigator Site 6112
Douglas, Queensland, 4814, Australia
Investigator Site 6123
Nambour, Queensland, 4560, Australia
Investigator Site 6111
Adelaide, South Australia, 5000, Australia
Investigator Site 6124
Bedford Park, South Australia, 5042, Australia
Investigator Site 6103
Elizabeth Vale, South Australia, 5112, Australia
Investigator Site 6122
Hobart, Tasmania, 7000, Australia
Investigator Site 6129
Epping, Victoria, 3076, Australia
Investigator Site 6127
Heidelberg, Victoria, 3084, Australia
Investigator Site 6125
Perth, Western Australia, 6000, Australia
Investigator Site 6130
Perth, Western Australia, 6000, Australia
Investigator Site 6118
Brisbane, Australia
Investigator Site 6126
Geelong, Australia
Investigator Site 6101
Kogarah, NSW2217, Australia
Investigator Site 6105
Melbourne, 3004, Australia
Investigator Site 6110
Nedlands, 6009, Australia
Investigator Site 6121
New Lambton, NSW2305, Australia
Investigator Site 6108
So Australia, Australia
Investigator Site 6119
Southport, 4215QLD, Australia
Investigator Site 2069
Calgary, Alberta, T2N 2T9, Canada
Investigator Site 2065
Edmonton, Alberta, T6G 2B7, Canada
Investigator Site 2064
Edmonton, Alberta, T6L 5X8, Canada
Investigator Site 2073
Red Deer, Alberta, T4N 4E7, Canada
Investigator Site 2059
Kelowna, British Columbia, V1Y 1E4, Canada
Investigator Site 2068
New Westminster, British Columbia, v3L3W4, Canada
Investigator Site 2066
Surrey, British Columbia, V3V 1Z2, Canada
Investigator Site 2057
Vancouver, British Columbia, V6Z1Y6, Canada
Investigator Site 2063
Victoria, British Columbia, V8R4R2, Canada
Investigator Site 2070
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Investigator Site 2048
Halifax, Nova Scotia, B3H 3A7, Canada
Investigator Site 2072
Sydney, Nova Scotia, B1P1P3, Canada
Investigator Site 2067
Hamilton, Ontario, L8L2X2, Canada
Investigator Site 2075
Kitchener, Ontario, N2M 1B2, Canada
Investigator Site 2058
London, Ontario, N6A 5A5, Canada
Investigator Site 2004
Newmarket, Ontario, L3Y 8C3, Canada
Investigator Site 2008
Scarborough Village, Ontario, M1E4B9, Canada
Investigator Site 2030
Thunder Bay, Ontario, P7B7C7, Canada
Investigator Site 2011
Toronto, Ontario, J6V2H2, Canada
Investigator Site 2012
Toronto, Ontario, M5B1W8, Canada
Investigator Site 2074
Laval, Quebec, H7M 3L9, Canada
Investigator Site 2020
Lévis, Quebec, G6V 4Z5, Canada
Investigator Site 2009
Montreal, Quebec, H1T 2M4, Canada
Investigator Site 2052
Montreal, Quebec, H2W1T8, Canada
Investigator Site 2001
Montreal, Quebec, H3H2R9, Canada
Investigator Site 2053
Québec, Quebec, G1R 2J6, Canada
Investigator Site 2007
Québec, Quebec, G1V4G5, Canada
Investigator Site 2071
Saint-Jérôme, Quebec, J7Z5T3, Canada
Investigator Site 2006
Terrebonne, Quebec, J6V2H2, Canada
Investigator Site 2010
Saint John, NBE2L4L2, Canada
Investigator Site 4212
Jihlavska, Brno, 62500, Czechia
Investigator Site 4201
Ústà nad Labem, Labem, 40113, Czechia
Investigator Site 4216
Liberec, Stare Mesto, 46063, Czechia
Investigator Site 4210
Brno, 656 91, Czechia
Investigator Site 4206
Hradec Králové, 500 05, Czechia
Investigator Site 4208
Jihlava, 58633, Czechia
Investigator Site 4214
Mladá Boleslav, 29350, Czechia
Investigator Site 4218
Nymburk, 288 02, Czechia
Investigator 4218
Nymburk, 425/9, Czechia
Investigator Site 4207
Olomouc, 755 20, Czechia
Investigator Site 4209
Ostrava, 70852, Czechia
Investigator Site 4205
Pilsen, 30599, Czechia
Investigator Site 4213
Prague, 10034, Czechia
Investigator Site 4204
Prague, 12802, Czechia
Investigator Site 4217
Prague, 150 06, Czechia
Investigator Site 4220
Prague, 6, Czechia
Investigator Site 4202
Ústà nad Labem, 401 13, Czechia
Investigator Site 4203
Znojmo, 66902, Czechia
Investigator Site 9502
Tbilisi, 0102, Georgia
Investigator Site 9508
Tbilisi, 0102, Georgia
Investigator Site 9504
Tbilisi, 0141, Georgia
Investigator Site 9509
Tbilisi, 0144, Georgia
Investigator Site 9510
Tbilisi, 0144, Georgia
Investigator Site 9501
Tbilisi, 0159, Georgia
Investigator Site 9505
Tbilisi, 0159, Georgia
Investigator Site 9506
Tbilisi, 0164, Georgia
Investigator Site 9503
Tbilisi, 0179, Georgia
Investigator Site 9507
Tbilisi, 0186, Georgia
Investigator Site 4921
Warendorf, Am Krankenhaus, 48231, Germany
Investigator Site 4932
Bad Friedrichshall, 74177, Germany
Investigator Site 4930
Bad Nauheim, 61231, Germany
Investigator Site 4928
Berlin, 12559, Germany
Investigator Site 4904
Bielefeld, 336 04, Germany
Investigator Site 4905
Bonn, 53105, Germany
Investigator Site 4923
Dortmund, 44137, Germany
Investigator Site 4912
Erfurt, 99089, Germany
Investigator Site 4907
Göttingen, 37075, Germany
Investigator Site 4922
Hamburg, 21075, Germany
Investigator Site 4929
Kassel, 34121, Germany
Investigator Site 4911
Kiel, 24105, Germany
Investigator Site 4901
Limburg, 65549, Germany
Investigator Site 4927
Lübeck, 23538, Germany
Investigator Site 4908
Magdeburg, 39120, Germany
Investigator Site 4902
Mainz, 55131, Germany
Investigator Site 4917
München, Germany
Investigator Site 4925
Nauen, 14641, Germany
Investigator Site 4915
Regensburg, 93053, Germany
Investigator Site 4906
Ulm, 89081, Germany
Investigator Site 3626
Pécs, Baranya, H-7624, Hungary
Investigator Site 3606
Székesfehérvár, Fejér, 8000, Hungary
Investigator Site 3602
Budapest, Gaal Jozsef, Hungary
Investigator Site 3605
Debrecen, Hajdú-Bihar, 4012, Hungary
Investigator Site 3607
Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary
Investigator Site 3614
Semmelweis, Kistarcsa, 2143, Hungary
Investigator Site 3616
Budapest, Pest County, 1076, Hungary
Investigator Site 3612
Budapest, Pest County, 1097, Hungary
Investigator Site 3603
Zalaegerszeg, Zala County, H-8900, Hungary
Investigator Site 3625
Balatonfüred, 8203, Hungary
Investigator Site 3604
Budapest, 1096, Hungary
Investigator Site 3622
Budapest, 1106, Hungary
Investigator Site 3619
Eger, 3300, Hungary
Investigator Site 3624
Hódmezővásárhely, 6800, Hungary
Investigator Site 3629
Sopron, 9400, Hungary
Investigator Site 3623
Szombathely, 9700, Hungary
Investigator Site 9110
Hyderabad, Andhra Pradesh, 500082, India
Investigator Site 9109
Secunderabad, Andhra Pradesh, 500003, India
Investigator Site 9119
Secunderabad, Andhra Pradesh, 500003, India
Investigator Site 9104
Ahmedabad, Gujarat, 380 014, India
Investigator Site 9111
Ahmedabad, Gujarat, 380052, India
Investigator Site 9108
Ahmedabad, Gujarat, 380060, India
Investigator Site 9117
Surat, Gujarat, 395007, India
Investigator Site 9115
Vadodara, Gujarat, 390 015, India
Investigator Site 9102
Vadodara, Gujarat, 390007, India
Investigator Site 9114
Bangalore, Karnataka, 560 0034, India
Investigator Site 9121
Bangalore, Karnataka, 560 052, India
Investigator Site 9113
Indore, Madhya Pradesh, 452008, India
Investigator Site 9101
Nagpur, Maharashtra, 440012, India
Investigator Site 9105
New Delhi, National Capital Territory of Delhi, 110076, India
Investigator Site 9103
Lucknow, Uttar Pradesh, 226003, India
Investigator Site 9118
Kolkata, West Bengal, 7000020, India
Investigator Site 9107
Kolkata, West Bengal, 700027, India
Investigator Site 3921
Brescia, Via L Bissolati, 57, Italy
Investigator Site 3908
Cecina, 57023, Italy
Investigator Site 3912
Colleferro, 00034, Italy
Investigator Site 3910
Ferrara, 44121, Italy
Investigator Site 3916
Massa, 54100, Italy
Investigator Site 3906
Milan, 20138, Italy
Investigator Site 3901
Monza, 20052, Italy
Investigator Site 3907
Napoli, 80131, Italy
Investigator Site 3920
Novara, 28100, Italy
Investigator Site 3918
Roma, 00135, Italy
Investigator Site 3902
Rome, 00168, Italy
Investigator Site 3909
Rome, 00189, Italy
Investigator Site 3903
Rozzano (MI), 20089, Italy
Investigator Site 3904
Siena, 53100, Italy
Investigator Site 9603
Bir Hassan, Jnah, Lebanon
Investigator Site 9601
Beirut, BEI, Lebanon
Investigator Site 9603
Beirut, Lebanon
Investigator Site 3126
Nieuwegein, CM, 3435, Netherlands
Investigator Site 3129
Goes, RA, 4462, Netherlands
Investigator Site 3120
Amstelveen, 1186 AM, Netherlands
Investigator Site 3128
Amsterdam, 1081 HV, Netherlands
Investigator Site 3117
Amsterdam, 1091 AC, Netherlands
Investigator Site 3125
Amsterdam, Netherlands
Investigator Site 3136
Breda, 4818, Netherlands
Investigator Site 3130
Delft, 2625 AD, Netherlands
Investigator Site 3108
Den Helder, 1782 GZ, Netherlands
Investigator Site 3105
Deventer, 7416 SE, Netherlands
Investigator Site 3102
Ede, 6716RP, Netherlands
Investigator Site 3134
Heerlen, 6419 PC, Netherlands
Investigator Site 3109
Hoogeveen, 7909 AA, Netherlands
Investigator Site 3101
Leeuwarden, Netherlands
Investigator Site 3118
Leiden, 2333 ZA, Netherlands
Investigator Site 3112
Purmerend, 1447 TC, Netherlands
Investigator Site 3107
Roosendaal, 4708 AE, Netherlands
Investigator Site 3104
Rotterdam, 3011 TD, Netherlands
Investigator Site 3106
Rotterdam, 3045 PM, Netherlands
Investigator Site 3123
Rotterdam, 3075 EA, Netherlands
Investigator Site 3131
Schiedam, 3118 JH, Netherlands
Investigator Site 3135
Sneek, 8601 ZK, Netherlands
Investigator Site 3103
Tilburg, 5022 CG, Netherlands
Investigator Site 3116
Utrecht, 3584 CX, Netherlands
Investigator Site 3124
Venlo, 5912 BL, Netherlands
Investigator Site 3113
Zaandam, 1502 DV, Netherlands
Investigator Site 6402
Takapuna, Auckland, 0622, New Zealand
Investigator Site 6405
Christchurch, 8011, New Zealand
Investigator Site 6404
Dunedin, 9054, New Zealand
Investigator Site 6401
Hamilton, 3240, New Zealand
Investigator Site 6406
Wellington, 6021, New Zealand
Investigator Site 4804
Inowrocław, Kuyavian-Pomeranian Voivodeship, 88-100, Poland
Investigator Site 4825
Wroc³aw, Lower Silesian Voivodeship, 53-114, Poland
Investigator Site4819
Puławy, Podkarpackie Voivodeship, 24-100, Poland
Investigator Site 4828
Gdansk, Pomeranian Voivodeship, 80-952, Poland
Investigator Site 4809
Bialystok, 15-276, Poland
Investigator Site 4813
Bialystok, 15-276, Poland
Investigator Site 4801
Bytom, 41-902, Poland
Investigator Site 4816
Stalowa Wola, 37-450, Poland
Investigator Site 4827
Szczecin, 70-111, Poland
Investigator Site 4812
Warsaw, 00-685, Poland
Investigator Site 4815
Warsaw, 01-809, Poland
Investigator Site 4806
Warsaw, 02-507, Poland
Investigator Site 4823
Warsaw, 04-628, Poland
Investigator Site 4824
Wroclaw, 50-367, Poland
Investigator Site 7026
Barnaui, 656099, Russia
Investigator Site 7021
Chelyabinsk, Russia
Investigator Site 7023
Irkutsk, 664079, Russia
Investigator Site 7020
Kazan', 420101, Russia
Investigator Site 7002
Kemerovo, 650002, Russia
Investigator Site 7017
Krasnoyarsk, Russia
Investigator Site 7024
Kursk, 305035, Russia
Investigator Site 7003
Moscow, 111539, Russia
Investigator Site 7015
Moscow, 119620, Russia
Investigator Site 7019
Moscow, 121552, Russia
Investigator Site 7018
Murmansk, 183047, Russia
Investigator Site 7004
Novosibirsk, 630008, Russia
Investigator Site 7027
Novosibirsk, Russia
Investigator Site 7022
Orenburg, 460040, Russia
Investigator Site 7016
Rostov-on-Don, 344068, Russia
Investigator Site 7009
Saint Petersburg, 191015, Russia
Investigator Site 7008
Saint Petersburg, 198205, Russia
Investigator Site 7007
Saint Petersburg, Russia
Investigator Site 7010
Saint Petersburg, Russia
Investigator Site 7013
Saint Petersburg, Russia
Investigator Site 7025
Saint Petersburg, Russia
Investigator Site 7005
Samara, 443070, Russia
Investigator Site 7006
Saratov, 410054, Russia
Investigator Site 7028
Saratov, Russia
Investigator Site 7011
Tomsk, 634012, Russia
Investigator Site 7012
Tyumen, 625026, Russia
Investigator Site 7001
Yekaterinburg, 620109, Russia
Investigator Site 8205
Busan, 602-715, South Korea
Investigator Site 8206
Busan, 602-739, South Korea
Investigator Site 8202
Cheongju-si, 361-711, South Korea
Investigator Site 8214
Daegu, 700-712, South Korea
Investigator Site 8213
Daejeon, 301-723, South Korea
Investigator Site 8203
Gwangju, 501-757, South Korea
Investigator Site 8204
Gyeonggi-do, 480-717, South Korea
Investigator Site 8210
Kangwon-do, 220-701, South Korea
Investigator Site 8209
Seoul, 130-702, South Korea
Investigator Site 8215
Seoul, 130-709, South Korea
Investigator Site 8212
Seoul, 135-710, South Korea
Investigator Site 8207
Seoul, 135-720, South Korea
Investigator Site 8201
Seoul, 152-703, South Korea
Investigator Site 8208
Suwon, 442-723, South Korea
Investigator Site 8211
Suwon, 443-721, South Korea
Investigator Site 3432
Badalona, Barcelona, 08916, Spain
Investigator Site 3428
Barcelona, Barcelona, 08025, Spain
Investigator Site 3402
Lleida, Lleida, 25198, Spain
Investigator Site 3420
Coslada, Madrid, 28820, Spain
Investigator Site 3419
Fuenlabrada, Madrid, 28942, Spain
Investigator Site 3409
Madrid, Madrid, 28007, Spain
Investigator Site 3413
Majadahonda, Madrid, 28222, Spain
Investigator Site 3415
Málaga, Malaga, 29010, Spain
Investigator Site 3421
Málaga, Malaga, 29010, Spain
Investigator Site 3411
Lorca, Murcia, 30800, Spain
Investigator Site 3416
Pamplona, Navarre, 31008, Spain
Investigator Site 3408
Vigo, Pontevedra, 36211, Spain
Investigator Site 3410
Vigo, Pontevedra, 36214, Spain
Investigator Site 3404
Oviedo, Principality of Asturias, 33006, Spain
Investigator Site 3414
Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38010, Spain
Investigator Site 3403
Valencia, Valencia, 46014, Spain
Investigator Site 3425
Galdakao, Vizcaya, 48960, Spain
Investigator Site 3435
Albacete, 02006, Spain
Investigator Site 3418
Barcelona, 08906, Spain
Investigator Site 3406
Girona, 17007, Spain
Investigator Site 3407
Huelva, 21005, Spain
Investigator Site 3430
Leganés, 28911, Spain
Investigator Site 3423
Madrid, 28040, Spain
Investigator Site 3401
Madrid, 28046, Spain
Investigator Site 3431
Pontevedra, 36071, Spain
Investigator Site 3424
Reus, 43206, Spain
Investigator Site 3434
Seville, 41009, Spain
Investigator Site 3422
Utrera, 41710, Spain
Investigator Site 3809
Dnipropetrovsk, 49006, Ukraine
Investigator Site 3807
Ivano-Frankivsk, 76014, Ukraine
Investigator Site 3806
Kharkiv, 61002, Ukraine
Investigator Site 3802
Kharkiv, 61018, Ukraine
Investigator Site 3803
Kharkiv, 61039, Ukraine
Investigator Site
Kharkiv, 61039, Ukraine
Investigator Site 3810
Kharkiv, Ukraine
Investigator Site 3801
Kiev, 02175, Ukraine
Investigator Site 3805
Kiev, Ukraine
Investigator Site 3808
Kiev, Ukraine
Investigator Site 3811
Lviv, Ukraine
Investigator Site 3813
Odesa, 65014, Ukraine
Investigator Site 3815
Odesa, Ukraine
Investigator Site 3814
Poltava, 36039, Ukraine
Related Publications (1)
Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836.
PMID: 24247616DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 19, 2010
First Posted
May 25, 2010
Study Start
May 1, 2010
Primary Completion
March 1, 2012
Study Completion
March 1, 2012
Last Updated
October 31, 2012
Record last verified: 2012-10